Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit

Rhea-AI Summary

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) announced its participation in the Precision in Clinical Trials Summit in Boston on May 1-2, 2023. Chief Medical Officer Dr. Joseph Stauffer will present Antibe’s clinical program for otenaproxesul, a drug designed to provide safer pain relief alternatives to opioids and NSAIDs, particularly addressing gastrointestinal side effects. Antibe's pipeline includes ATB-352, targeting specialized pain indications and aims to develop new therapies for inflammatory bowel disease. This summit offers a platform for clinical trial professionals to discuss innovations in the field.

Positive

• Participation in the Precision in Clinical Trials Summit highlights Antibe's commitment to advancing its clinical development.
• Otenaproxesul is positioned as a safer alternative to opioids and NSAIDs, addressing significant market needs.
• Pipeline expansion with ATB-352 targeting specialized pain and future focus on inflammatory bowel disease (IBD) reflects strategic growth.

Negative

• None.

TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the Precision in Clinical Trials Summit being held in Boston on May 1 – 2, 2023. Dr. Joseph Stauffer, Antibe’s Chief Medical Officer, will deliver a live presentation discussing Antibe’s clinical program for otenaproxesul:

Date: Tuesday, May 2, 2023
Time: 12:00 noon (Eastern Time)
Location: Revere Hotel Boston Common

An invitation-only event that addresses the needs of organizations conducting clinical trials at a local and global level, the 20th PCT Boston Clinical Trials Summit is a unique platform for clinical trial experts to share information and discuss the latest innovations.

About Antibe Therapeutics Inc.

Antibe is a clinical-stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and today’s NSAIDs for acute pain. Antibe’s second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company’s next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005194/en/

Antibe Therapeutics Inc.

Christina Cameron

VP Investor Relations

+1 416-577-1443

christina@antibethera.com

Source: Antibe Therapeutics Inc.

FAQ

What is the purpose of Antibe's presentation at the Precision in Clinical Trials Summit?

Antibe's presentation aims to discuss the clinical program for its lead drug, otenaproxesul, focusing on its potential as a safer alternative for pain management.

When is Antibe's presentation scheduled during the Precision in Clinical Trials Summit?

Antibe's presentation is scheduled for May 2, 2023, at 12:00 noon Eastern Time.

What are the key drugs in Antibe's pipeline?

Antibe's key drugs include otenaproxesul and ATB-352, with a focus on pain relief and potential treatments for inflammatory bowel disease.

How does otenaproxesul differ from traditional NSAIDs?

Otenaproxesul is designed to provide pain relief with a lower risk of gastrointestinal ulcers and bleeding compared to traditional NSAIDs.

What impact could Antibe's therapies have on the market?

Antibe's therapies aim to address critical gaps in pain management and IBD treatment, potentially capturing significant market share.